Pierre N. Tariot

发表

Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

Robert A. Dean, David S Knopman, Jeffrey Kaye, 2006, Neurology.

Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan

Eric M. Reiman, Helen Street, P. Tariot, 2018, Alzheimer's & dementia.

CAP—advancing the evaluation of preclinical Alzheimer disease treatments

Reisa A. Sperling, Paul S. Aisen, Eric M. Reiman, 2016, Nature Reviews Neurology.

Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years

Gerald van Belle, Jeremy M. Silverman, Kathleen A. Welsh-Bohmer, 2008, Alzheimer's & Dementia.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease

Veronique Bohbot, Clifford R. Jack, Alan C. Evans, 2015, Scientific Data.

Screen and Intervene: The Importance of Early Detection and Treatment of Alzheimer's Disease

Gregory Jicha, James E. Galvin, Pierre N. Tariot, 2020 .

Ushering in the study and treatment of preclinical Alzheimer disease

Richard J. Caselli, Kewei Chen, Napatkamon Ayutyanont, 2013, Nature Reviews Neurology.

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

John Seibyl, Anthony E. Lang, Stanley Fahn, 2000, JAMA.

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

Kewei Chen, Napatkamon Ayutyanont, Adam S. Fleisher, 2014, Alzheimer's & Dementia.